Anticancer evaluation of a novel dithiocarbamate hybrid as the tubulin polymerization inhibitor

SummaryNovel quinoline-dithiocarbamate hybrids were synthesized and designed by the molecular hybridization strategy. All these derivatives were evaluated for their antiproliferative activity against three selected cancer cell lines (MGC-803, HepG-2 and PC-3). Among them, compound10c displayed the best antiproliferative activity against PC-3 cells with an IC50 value of 0.43  μM. Celluar mechanisms investigated that compound10c could inhibit the migration against PC-3 cells by regulation the expression levels of E-cadherin and N-cadherin. Compound10c induced morphological changes of PC-3 cells and regulated apoptosis-related proteins (Bcl-2, Bax and Cleaved-Parp). In addition, compound10c inhibited tubulin polymerization in vitro with an IC50 value of 4.02  μM. Importantly, compound10c inhibited the growth of PC-3 cells in vivo with the low toxicity toward mice. These results suggested that compound10c might be an antitumor agent with potential for treating prostate cancer.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Condition:   Prostate Adenocarcinoma Intervention:   Combination Product: MVA-BN-Brachyury Sponsors:   University of Utah;   Bavarian Nordic;   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Recurrent Prostate Cancer Intervention:   Drug: Nivolumab Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Prostate Adenocarcinoma;   Prostate Neoplasm;   Prostate Cancer Metastatic;   Castration-resistant Prostate Cancer Interventions:   Drug: Talazoparib;   Drug: Temozolomide Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
VANCOUVER and HOUSTON, July 15, 2019 -- (Healthcare Sales &Marketing Network) - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI), a pharmaceutical company focused on the developing novel therapies for the treatmen... Biopharmaceuticals, Oncology, Personnel ESSA Pharma, prostate cancer, aniten
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
ConclusionsIpatasertib, at the monotherapy MTD of 600  mg/day and MAD of 400 mg/day in combination with abiraterone and prednisolone, was safe and tolerable in Japanese patients with solid tumors.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionPCC alone is not enough to improve a cancer survivor ’s confidence in their ability to manage their health in the presence of multiple chronic conditions.Implications for Cancer SurvivorsCancer survivors with multiple chronic conditions need ongoing support, in addition to PCC, that render them prepared to manage their health after cancer.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research
ConclusionHigh-resolution micro-ultrasound identified clinically significant cancer that would have, otherwise, been missed by both MRI fusion and systematic biopsy and was useful in both biopsy na ïve and repeat negative patients. Early results from this small, single-center cohort are promising, particularly given the ease with which micro-ultrasound can replace the conventional ultrasound in standard prostate biopsy procedures.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
ConclusionOur findings suggest that PA during AS for PCa does not significantly influence time to curative treatment.
Source: Cancer Causes and Control - Category: Cancer & Oncology Source Type: research
In this study, we found the AgNPs effectively induces cytotoxicity, ROS and apoptosis by modulation of intrinsic apoptoic Bcl2, Bclxl, Bax and Caspase 3 protein expressions in LNCap cell lines. Based on the study, synthesis of AgNPs from S. miltiorrhiza shows eco-friendly and it exhibits antimicrobial and anticarcinogenic effects. PMID: 31299869 [PubMed - in process]
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Prostate Cancer | Toxicology